NDAORALTABLET, EXTENDED RELEASE
Approved
Jan 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
14
Data completeness
3/8 — Basic
TOPROL-XL (metoprolol succinate) by CorMedix is 1 -selective (cardioselective) adrenergic receptor blocking agent. First approved in 1992.
Drug data last refreshed 7h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TOPROL-XL is an extended-release oral tablet formulation of metoprolol succinate, a beta-1-selective adrenergic receptor blocking agent approved in 1992. It is indicated for hypertension, angina pectoris, and heart failure by reducing cardiac oxygen demand and sympathetic outflow. The drug works through competitive antagonism of catecholamines at cardiac adrenergic sites, thereby decreasing heart rate, myocardial contractility, and blood pressure.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting smaller brand team and focus on cost-containment strategies rather than growth initiatives.
Mechanism of Action
1 -selective (cardioselective) adrenergic receptor blocking agent. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta 2 -adrenoreceptors, chiefly located in the bronchial and vascular musculature. Metoprolol has no intrinsic…
Indications
Worked on TOPROL-XL at CorMedix? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.